BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.62
-0.28 (-3.15%)
At close: May 8, 2026, 4:00 PM EDT
8.60
-0.02 (-0.22%)
After-hours: May 8, 2026, 7:44 PM EDT
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 9 analysts that cover BioCryst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $21.11, which forecasts a 144.90% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $32.
Price Target: $21.11 (+144.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 6 | 5 | 5 | 5 | 5 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 11 | 11 | 11 | 11 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $25 → $28 | Buy | Maintains | $25 → $28 | +224.83% | May 7, 2026 |
| Wedbush | Wedbush | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +143.62% | May 7, 2026 |
| Needham | Needham | Strong Buy Maintains $18 → $16 | Strong Buy | Maintains | $18 → $16 | +85.61% | May 6, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $14 → $13 | Buy | Maintains | $14 → $13 | +50.81% | Jan 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +271.23% | Dec 15, 2025 |
Financial Forecast
Revenue This Year
663.22M
from 874.84M
Decreased by -24.19%
Revenue Next Year
747.06M
from 663.22M
Increased by 12.64%
EPS This Year
0.33
from 1.21
Decreased by -72.87%
EPS Next Year
0.54
from 0.33
Increased by 63.88%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 695.1M | 841.8M | ||||||
| Avg | 663.2M | 747.1M | ||||||
| Low | 627.2M | 672.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -20.5% | 26.9% | ||||||
| Avg | -24.2% | 12.6% | ||||||
| Low | -28.3% | 1.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 0.67 | 1.11 | ||||||
| Avg | 0.33 | 0.54 | ||||||
| Low | 0.01 | 0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -44.5% | 239.0% | ||||||
| Avg | -72.9% | 63.9% | ||||||
| Low | -99.2% | -97.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.